Aeterna Zentaris Inc. (NASDAQ:AEZS) and CASI Pharmaceuticals Inc. (NASDAQ:CASI) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aeterna Zentaris Inc.||26.88M||2.64||4.19M||0.53||7.08|
|CASI Pharmaceuticals Inc.||N/A||0.00||27.47M||-0.30||0.00|
Demonstrates Aeterna Zentaris Inc. and CASI Pharmaceuticals Inc. earnings per share, gross revenue and valuation.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Aeterna Zentaris Inc.||15.59%||137.5%||29.7%|
|CASI Pharmaceuticals Inc.||0.00%||-30.7%||-28.7%|
Volatility & Risk
A beta of 1.23 shows that Aeterna Zentaris Inc. is 23.00% more volatile than Standard and Poor’s 500. CASI Pharmaceuticals Inc.’s 1.22 beta is the reason why it is 22.00% more volatile than Standard and Poor’s 500.
The Current Ratio and a Quick Ratio of Aeterna Zentaris Inc. are 3.6 and 3.3. Competitively, CASI Pharmaceuticals Inc. has 14.6 and 14.6 for Current and Quick Ratio. CASI Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Aeterna Zentaris Inc.
In next table is given Aeterna Zentaris Inc. and CASI Pharmaceuticals Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Aeterna Zentaris Inc.||0||0||0||0.00|
|CASI Pharmaceuticals Inc.||0||0||1||3.00|
On the other hand, CASI Pharmaceuticals Inc.’s potential upside is 109.58% and its consensus target price is $7.
Insider and Institutional Ownership
The shares of both Aeterna Zentaris Inc. and CASI Pharmaceuticals Inc. are owned by institutional investors at 21.4% and 21.5% respectively. Aeterna Zentaris Inc.’s share owned by insiders are 0.6%. Insiders Comparatively, owned 18.2% of CASI Pharmaceuticals Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Aeterna Zentaris Inc.||-9.57%||-1.31%||23.53%||110%||122.35%||28.57%|
|CASI Pharmaceuticals Inc.||-8.89%||-5.2%||-15.9%||-52.67%||-5.48%||-18.41%|
For the past year Aeterna Zentaris Inc. has 28.57% stronger performance while CASI Pharmaceuticals Inc. has -18.41% weaker performance.
Aeterna Zentaris Inc. beats on 9 of the 11 factors CASI Pharmaceuticals Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.